AbbVie Inc. Press Releases

ABBV 
$53.74
*  
0.56
1.05%
Get ABBV Alerts
*Delayed - data as of Jul. 28, 2014  -  Find a broker to begin trading ABBV now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    ABBV Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

AbbVie Reports Second-Quarter 2014 Financial Results
7/25/2014 7:47:00 AM - PR Newswire

AbbVie to Host Second-Quarter Earnings Conference Call
7/23/2014 12:44:00 PM - PR Newswire

Parkinson's Organizations Unite to Serve Patients and Families Through National "Partners in Parkinson's" Initiative
7/22/2014 11:00:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
7/18/2014 6:17:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
7/18/2014 6:14:00 AM - PR Newswire

AbbVie Announces Inaugural Week of Possibilities Volunteer Program to Support Six Schools in North Chicago, Ill., and Worcester, Mass.
7/16/2014 10:00:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
7/8/2014 7:50:00 AM - PR Newswire

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer
6/26/2014 8:00:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/25/2014 8:45:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/25/2014 7:29:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/23/2014 7:45:00 AM - PR Newswire

Shire Confirms Rejection of AbbVie Proposal
6/20/2014 4:22:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/19/2014 11:48:00 PM - PR Newswire

AbbVie Declares Quarterly Dividend
6/19/2014 11:28:00 AM - PR Newswire

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
6/17/2014 2:00:00 AM - PR Newswire

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
6/16/2014 7:30:00 AM - Business Wire

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
6/13/2014 3:34:00 PM - PR Newswire

AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
6/11/2014 2:00:00 AM - PR Newswire

AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
6/10/2014 8:00:00 AM - PR Newswire

AbbVie to Present at Jefferies 2014 Global Healthcare Conference
6/3/2014 8:30:00 AM - PR Newswire

AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting
5/31/2014 8:00:00 AM - PR Newswire

AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting
5/30/2014 8:00:00 AM - PR Newswire

The Michael J. Fox Foundation and AbbVie Launch "Partners in Parkinson's"
5/27/2014 9:28:00 AM - PR Newswire

AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis
5/20/2014 3:49:00 PM - PR Newswire

Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX
5/20/2014 8:50:00 AM - PR Newswire